BioCentury
ARTICLE | Clinical News

Recilisib sodium: Phase I data

October 22, 2012 7:00 AM UTC

A placebo-controlled Phase I trial in 32 healthy volunteers showed that 50-300 mg doses of subcutaneous Ex-RAD were well tolerated with no clinically significant treatment-related systemic toxicity re...